Potential AstraZeneca-Gilead deal to face political, strategic hurdles

Political opposition from both Britain and America could derail any attempt at a deal, especially given the backdrop of the Covid-19 outbreak. The timing is also questionable, as while Gilead is in the middle of a turnaround, AstraZeneca is well positioned and has a strong pipeline, analysts said.